CLDXNasdaq

Celldex Therapeutics, Inc.

Alert me on CLDX

Insider buys, 6 months

Congress trades, 6 months

Signals, 6 months

Six months

After each filing

Nov 18, 2025 Sale Wright Richard M. Insider

1 week

+3.4%S&P +2.3%

1 month

−1.1%S&P +2.5%

3 months

−10.0%S&P +4.8%

6 months

+19.5%S&P +13.2%

Every purchase and sale on this ticker reported by a member of Congress or an insider, measured from the close of the first trading day after it became public to the close 1 week, 1 month, 3 months and 6 months later, each beside the S&P over the same days.

Filings for CLDX 7 held · newest first

Loading the filings.

Signal history

No signal for this ticker yet. A signal is written when insider buying here scores one dot or more.

Stakes

Aug 18, 2025 Schedule 13G

Bellevue Group AG: 5.4%, 3,617,669 shares

Sep 30, 2025 Schedule 13G, amended

Commodore Capital LP: 4.6%, 3,028,335 shares

Sep 30, 2025 Schedule 13G, amended

T. Rowe Price Associates, Inc.: 3.6%, 2,382,701 shares

Oct 31, 2025 Schedule 13G, amended

Wellington Management Group LLP: 11.1%, 7,394,746 shares

Schedule 13D is filed within 5 business days of crossing 5 percent by an investor who may seek to influence the company. Schedule 13G is filed by a passive holder, and a large institution has up to 45 days after the quarter end.

Government contracts, last 12 months

Awards of $10M and up, from USAspending · context, not a signal

No contracts of $10M or more in the last 12 months.

Lobbying

Last four quarters

$60KQ3 2025

$60KQ4 2025

$60KQ1 2026

$90KQ2 2026

Up 50 percent from Q1 2026. Reported to the Senate each quarter by the firms it hires.Original report ↗

Read from LDA.gov on Sep 23, 2026. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.